In addition, we observed activation of SMAD2/3 signaling in imatinib-treated K562 and KU812 CML cells; however, this activation was lower in L523I-expressing cells than in KLC2-WT cells (Fig. 4B,C). Here, SMAD2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.